BACKGROUND AND PURPOSE: To examine the role of adjuvant chemoradiation (CRT) in patients with resected ampullary adenocarcinoma. MATERIALS AND METHODS: The records of patients who underwent curative surgery for ampullary adenocarcinoma at a single institution between 1992 and 2007 were reviewed. Final analysis included 111 patients, 45% of which also received adjuvant CRT. RESULTS: Median overall survival (OS) was 36.2 months for all patients. Adverse prognostic factors for OS included T stage (T3/4 vs. T1/T2, p=0.046), node status (positive vs. negative, p<0.001), and histological grade (grade 3 vs. 1/2, p=0.09). Patients receiving CRT were more likely to have advanced T-stage (p=0.001), node positivity (p<0.001), and poor histologic grade (p=0.015). Patients who received CRT were also significantly younger (p=0.001). On univariate analysis, adjuvant CRT failed to result in a significant difference in survival when compared to surgery alone (median OS: 33.4 vs. 36.2 months, p=0.969). Patients with node-positive resections who underwent CRT had a non-significant improvement in survival (median OS: 21.6 vs. 13.0 months, p=0.092). Thirty-three percent of patients developed distant metastasis. Common sites of distant metastasis included liver (23%) and peritoneum (7%). CONCLUSIONS: Adjuvant chemoradiation following curative resection for ampullary adenocarcinoma did not lead to a statistically significant benefit in overall survival. A significant proportion of patients still developed distant metastatic disease suggesting a need for more effective systemic adjuvant therapy.
BACKGROUND AND PURPOSE: To examine the role of adjuvant chemoradiation (CRT) in patients with resected ampullary adenocarcinoma. MATERIALS AND METHODS: The records of patients who underwent curative surgery for ampullary adenocarcinoma at a single institution between 1992 and 2007 were reviewed. Final analysis included 111 patients, 45% of which also received adjuvant CRT. RESULTS: Median overall survival (OS) was 36.2 months for all patients. Adverse prognostic factors for OS included T stage (T3/4 vs. T1/T2, p=0.046), node status (positive vs. negative, p<0.001), and histological grade (grade 3 vs. 1/2, p=0.09). Patients receiving CRT were more likely to have advanced T-stage (p=0.001), node positivity (p<0.001), and poor histologic grade (p=0.015). Patients who received CRT were also significantly younger (p=0.001). On univariate analysis, adjuvant CRT failed to result in a significant difference in survival when compared to surgery alone (median OS: 33.4 vs. 36.2 months, p=0.969). Patients with node-positive resections who underwent CRT had a non-significant improvement in survival (median OS: 21.6 vs. 13.0 months, p=0.092). Thirty-three percent of patients developed distant metastasis. Common sites of distant metastasis included liver (23%) and peritoneum (7%). CONCLUSIONS: Adjuvant chemoradiation following curative resection for ampullary adenocarcinoma did not lead to a statistically significant benefit in overall survival. A significant proportion of patients still developed distant metastatic disease suggesting a need for more effective systemic adjuvant therapy.
Authors: J H Klinkenbijl; J Jeekel; T Sahmoud; R van Pel; M L Couvreur; C H Veenhof; J P Arnaud; D G Gonzalez; L T de Wit; A Hennipman; J Wils Journal: Ann Surg Date: 1999-12 Impact factor: 12.969
Authors: M A Talamini; R C Moesinger; H A Pitt; T A Sohn; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron Journal: Ann Surg Date: 1997-05 Impact factor: 12.969
Authors: Sunil Krishnan; Vishal Rana; Douglas B Evans; Gauri Varadhachary; Prajnan Das; Sumita Bhatia; Marc E Delclos; Nora A Janjan; Robert A Wolff; Christopher H Crane; Peter W Pisters Journal: Int J Radiat Oncol Biol Phys Date: 2007-11-05 Impact factor: 7.038
Authors: John T Miura; Thejus T Jayakrishnan; Albert Amini; Fabian M Johnston; Susan Tsai; Beth Erickson; Edward J Quebbeman; Kathleen K Christians; Douglas B Evans; T Clark Gamblin; Kiran K Turaga Journal: J Gastrointest Surg Date: 2014-08-27 Impact factor: 3.452
Authors: Michelle D Reid; Serdar Balci; Nobuyuki Ohike; Yue Xue; Grace E Kim; Takuma Tajiri; Bahar Memis; Ipek Coban; Anil Dolgun; Alyssa M Krasinskas; Olca Basturk; David A Kooby; Juan M Sarmiento; Shishir K Maithel; Bassel F El-Rayes; Volkan Adsay Journal: Mod Pathol Date: 2016-09-02 Impact factor: 7.842
Authors: Jim Zhong; Manisha Palta; Christopher G Willett; Shannon J McCall; Frances McSherry; Douglas S Tyler; Hope E Uronis; Brian G Czito Journal: J Gastrointest Oncol Date: 2014-12
Authors: Manisha Palta; Pretesh Patel; Gloria Broadwater; Christopher Willett; Joseph Pepek; Douglas Tyler; S Yousuf Zafar; Hope Uronis; Herbert Hurwitz; Rebekah White; Brian Czito Journal: Ann Surg Oncol Date: 2011-11-02 Impact factor: 5.344
Authors: Adriana Romiti; Viola Barucca; Angelo Zullo; Ida Sarcina; Roberta Di Rocco; Chiara D'Antonio; Marco Latorre; Paolo Marchetti Journal: World J Gastrointest Oncol Date: 2012-03-15
Authors: Jim Zhong; Manisha Palta; Christopher G Willett; Shannon J McCall; Anuradha Bulusu; Douglas S Tyler; Rebekah R White; Hope E Uronis; Theodore N Pappas; Brian G Czito Journal: J Gastrointest Oncol Date: 2013-03